Astria Therapeutics, Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has entered into a licensing agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of navenibart in Japan. Navenibart is a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 development for the preventative treatment of hereditary angioedema $(HAE)$. Under the agreement, Astria will receive an upfront payment of $16 million, with potential additional commercialization and sales milestones totaling $16 million. The company is also eligible for tiered royalties based on net sales, reaching up to 30%, and will receive partial reimbursement for Phase 3 costs. Kaken will support the ALPHA-ORBIT Phase 3 trial, handle regulatory submissions in Japan, and share in the costs of the Phase 3 program. No results from the Phase 3 trial have been presented as of the announcement.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。